Nautilus reports first revenue of $0.2 million and drops 2027 broadscale kit target
Nautilus Biotechnology reported second quarter 2026 revenue of $0.2 million, its first revenue, and a net loss of $14.5 million, down from $15.0 million a year earlier. The company also said its broadscale assay will not reach general availability in 2027 at its target specifications, and it is shifting resources toward its proteoform products, which it says will not change its broader financial assumptions.
Key points
- Q2 2026 revenue was $0.2 million, mainly grant revenue from The Michael J. Fox Foundation, plus service revenue from its first Iterative Mapping Early Access Program sales.
- Operating expenses fell 7% to $15.9 million from $17.1 million, and net loss narrowed to $14.5 million from $15.0 million.
- Broadscale assay did not meet targets for a 2027 general availability kit; the company will report a commercial timeline at a future date.
- Voyager platform launch is expected in early 2027, with cash, cash equivalents and investments of $129.2 million as of June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.